PT  - JOURNAL ARTICLE
AU  - Margaret L. Peters
AU  - Mandy Leonard
AU  - Angelo A. Licata
TI  - Role of alendronate and risedronate in preventing and treating osteoporosis
DP  - 2001 Nov 01
TA  - Cleveland Clinic Journal of Medicine
PG  - 945--951
VI  - 68
IP  - 11
4099  - http://www.ccjm.org/content/68/11/945.short
4100  - http://www.ccjm.org/content/68/11/945.full
SO  - Cleve Clin J Med2001 Nov 01; 68
AB  - Alendronate and risedronate, the two oral bisphosphonates approved in the United States for preventing and treating osteoporosis, have never been compared in direct head-to-head trials, but they appear to have similar pharmacokinetics, drug interactions, adverse effect profiles, and efficacy. Alendronate, however, can be given as a once-weekly dose, whereas risedronate is not yet available in this dosage form. On the other hand, alendronate is not approved for preventing glucocorticoid-induced osteoporosis, whereas risedronate carries this indication.